Trial
NCT00862836
Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Ovarian Cancer
Intervention
Vandetanib
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-10